A Phase II Trial of Sirolimus for Complex Renal Angiomyolipoma

Sirolimus for Complex Renal Angiomyolipoma

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002287

Enrollment

Unknown

Registered

2012-06-20

Start date

2012-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal angiomyolipoma

Interventions

1:Oral sirolimus once daily

2:No treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Complex renal angiomyolipoma is defined as either giant renal angiomyolipoma in an anatomical or functional solitary kidney or bilateral giant renal angiomyolipoma, surgical excision of which may be led to renal insufficiency or uremia.

Exclusion criteria

Exclusion criteria: 1. Angiomyolipoma embolization or bleeding within 12 months; 2. Suspicion of renal cell carcinoma; 3. Ongoing or planned pregnancy; 4. Lactation.

Design outcomes

Primary

Measure	Time frame
Objective response as assessed by RECIST criteria;Adverse event;	—

Contacts

Public ContactTao Lin

dr_taolin@163.com+86 18980602093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026